Astrazeneca SWOT Analysis
The second largest pharmaceutical and biologics company Astra Zeneca was founded in 1999 including Astra and Zeneca groups from Sweden and UK respectively. Its main office is in London.
• AstraZeneca is very young in its age but still reputed so well that in ranks seventh by revenue among world’s pharmaceutical companies.
• Indexed in FTSE 100 Index and OMX and New York Stock Exchange have labeled it secondarily.
• Total revenue of the company is nearly $34 billion and it has continuously been increasing successive years.
• Deals with a wide variety of medication and therapies including cardiovascular, tenderness, contagion, neuroscience, gastrointestinal respiratory and cancer and also proved beneficial (Grill and Hansen, 2007).
• Strong impression in U.S industry as well as Sweden, being a good competitor to their industries.
• According to recent calculations almost 70,000 people are employed in this organization, 11, 000 being employed in research and development sector in its head quarter alone.
• Focusing on Implants in diseases like cancer, infection and Alzheimer’s disease
• Medication and certain treatments for central nervous system are also being focused.
• Strategic partnering and business development refines its strategies to emerge successful in emerging global competition.
• Their marketing strategy involves the mass production of their new brands replacing the same products by other companies, that’s why losing patent licensing cannot lose their market reputation.
• Research neither is not only based on in licensing system but the company also invite the ex licensing of the researchers for the emergence of the new deals and products (Conniff, 2008).
• The company has faced lawsuit trials for being accused in maltreatment and extremist by their anti psychotic drug.
• Working environment is not up to the mark as the company has been sued for harassment cases in past.
• The company has been handled by incompetent leaders, which defrauded the company posing it a great loss.
• Totally new item are very seldom introduced, most of the times the entire brands are copied and this act is recently blocked by the judges.
• Collaboration with 1000 external partners would make it possible for insertion of new opportunities and ideas for global marketing and worldwide innovations.
• The company is trying to reaffirm its marketing strategy by replacing interactions of consumers in social media environments with social media engagement (Gladwell, 2004).
• Stakeholders are being negotiated with for quick turnaround.
• AstraZeneca is planning to become a purely research organization by shifting its manufacture terminal overseas for cutting the manufacture costs.
• Company settled the transfer mispricing tax issue by paying £505 million.
• Research and development sector is not very successful pertaining to patent protective production, which may harm the business deals.
• Political pressure is being faced from Europe and United States for increased accessibility of drugs.
1. Conniff, Richard. (2008). The Natural History of the Rich: A Field Guide. W. W. Norton. p. 126.
2. Grill, Markus and Hansen, Hans. (2007). "Vorsicht, Pharma! Wie die Industrie Ärzte manipuliert und Patienten täuscht." Published in issue of Stern Germany; pp. 100-107.
3. Gladwell, Malcolm. (2004). "High Prices: How to think about prescription drugs". The New York.